June 2024 PVRI Community Call with Julien Grynblat, David Montani and Stravros Zanos

Kholdani and colleagues describe patient characteristics, completeness of diagnostic testing, treatment patterns, risk characteristics, and outcomes of a large cohort of patients with pulmonary arterial hypertension seen at an academic pulmonary hypertension center over a 20-year period.

Epoprostenol is a prostaglandin that was first identified by investigators in 1976 and found to be a potent vasodilator and inhibiter of platelet aggregation, initially in animal studies and subsequently in humans.

The therapeutic value of lipid-lowering drugs in pulmonary vascular disease remains uncertain due to insufficient studies and evidence. This study aims to investigate the causal effects of lipid-lowering drugs (specifically, inhibitors of APOB, CETP, HMGCR, NPC1L1, and PCSK9) on pulmonary vascular diseases using a Mendelian randomization (MR) approach. 

Patients with borderline pulmonary hypertension (PH) often experience shortness of breath or exacerbation of PH during exercise, known as exercise-induced PH. However, the pathogenesis of exercise-induced post-capillary PH (post-EIPH) and its treatment strategies remain unclear.